期刊文献+

IL-22、IL-27、VEGF、TF及TFPI鉴别良恶性胸腔积液的应用价值研究 被引量:1

Study on application value of IL-22,IL-27,VEGF,TF and TFPI in identification of benign and malignant pleural effusion
下载PDF
导出
摘要 目的探讨白细胞介素(IL)-2、IL-27、血管内皮生长因子(VEGF)、组织因子(TF)及组织因子途径抑制物(TFPI)鉴别良恶性胸腔积液的应用价值。方法采用酶联免疫吸附测定(ELISA)法检测67例良性胸腔积液及73例恶性胸腔积液的IL-22、IL-27、VEGF、TF及TFPI 5种分子标志物的水平。结果恶性胸腔积液组的IL-22、IL-27、VEGF、TF及TFPI水平均显著高于良性胸腔积液组,差异有统计学意义(P<0.05)。多因素Logistic回归分析显示,只有VEGF是胸腔积液良恶性鉴别的独立影响因素。结论胸腔积液IL-22、IL-27、VEGF、TF及TFPI的检测有助于临床诊治良恶性胸腔积液患者,其中VEGF可做为胸腔积液良恶性鉴别的独立影响因素。 Objective To explore the application value of IL-22,IL-27,VEGF,TF and TFPI in the identification of benign and malignant pleural effusion.Methods The enzyme-linked immunosorbent assay(ELISA)was adopted to detected the five molecular markers levels of IL-22,IL-27,VEGF,TF and TFPI levels in 67 cases of benign pleural effusion and 73 cases of malignant pleural effusion.Results The levels of IL-22,IL-27,VEGF,TF and TFPI in the malignant pleural effusion group was significantly higher than those in the benign pleural effusion group,and the differences were statistically significant(P0.05).The multi-factor Logistic aggression analysis results showed that only VEGF was an independent influencing factor for identifying benign and malignant pleural effusion.Conclusion The detection of pleural effusion IL-22,IL-27,VEGF,TF and TFPI is helpful for clinical diagnosis and treatment of the patients with benign and malignant pleural effusion,in which VEGF can be regarded as an independent factor influencing the identification of benign and malignant pleural effusion.
出处 《国际检验医学杂志》 CAS 2016年第22期3111-3112,共2页 International Journal of Laboratory Medicine
基金 广东省深圳市龙岗区科技发展资金医疗卫生(扶持类)项目(YLWS20150513173417559)
关键词 良恶性胸腔积液 白细胞介素-22 白细胞介素-27 血管内皮生长因子 组织因子 benign and malignant pleural effusion IL-22 IL-27 VEGF TF
  • 相关文献

参考文献5

二级参考文献57

  • 1谢鹏雁.腹水鉴别的基本思路[J].中国医刊,2006,41(9):2-3. 被引量:6
  • 2朱艳玲,赵明祥,吴珊.脑血管病并发神经源性肺水肿凝血/炎症机制的研究[J].山东医药,2007,47(16):22-23. 被引量:6
  • 3-.首届中华血液学会全国血栓与止血学会议有关凝血疾病的诊断标准(修订案)[J].中华血液学杂志,1987,8:183-183.
  • 4Vespa PM, Bleck TP. Neurogenic pulmonary edema and other mechanisma of inpaired oxygenation after aneurysmal subarachnoid hemorrhage [J]. Neurocrit Care,2004,1(2):157-170.
  • 5Dugina TN, Kiseleva FV, Chistov IV, et al. Receptors of the PAR family as a link between blood coagulation and inflammation [J]. Biochemistry, 2002,67(1):65-74.
  • 6Szotowski B, Antoniak S, Poller W, et al. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines [J]. Circulation Research,2005,96(12):1233.
  • 7Westrick RJ, Bodary PF, Xu Z, et al. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice [J]. Circulation, 2001,103 (25):3044.
  • 8Falciani M, Gori A M, Fedi S, et al. Elevated tissue factor and tissue factor pathway inhibitor circulatory levels in ischemia heart disease patients. Thromb &amp;Haemotasis, 1998,79: 495 - 499.
  • 9Hirofumi S, Hisao O, Hirofami Y, et al. Heightened tissue factor pathway inhibitor and progrosis in patients with unstable agina. Circulation, 1999, 99: 2908-2913.
  • 10Parker P A, Sabrah T, Cap M, et al. Realation of vas cular oxidative stress, a-tocopherol, and hypercholesterlemia to early atherosclerosis in hamsters. Aterio scler Thromb Vasc Biol, 1995, 15: 349-354.

共引文献58

同被引文献7

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部